Jiang Zheng, Wei Junwei, Liang Yunxiang, Peng Nan, Li Yingjun
State Key Laboratory of Agricultural Microbiology, College of Life Science and Technology, Huazhong Agricultural University, Wuhan 430070, China.
Antibiotics (Basel). 2020 Oct 19;9(10):714. doi: 10.3390/antibiotics9100714.
Antibiotic resistance is becoming the biggest threat to global health. At the same time, phage therapy is witnessing a return of interest. The therapeutic use of bacteriophages that infect and kill bacteria is a suitable strategy to combat antibiotic resistance. Furthermore, bacteriophages are increasingly used in combination with standard antibiotics against drug-resistant pathogens. Interestingly, we found that the engineered mycobacteriophage phAE159 and natural phage D29 cannot infect the in the presence of kanamycin, hygromycin or streptomycin, but the phage infection was not affected in the presence of spectinomycin. Based on a series of studies and structural analysis of the above four aminoglycoside antibiotics, it could be speculated that the amino sugar group of aminoglycoside might selectively inhibit mycobacteriophage DNA replication. Our discovery that broad-spectrum antibiotics inhibit phage infection is of great value. This study will provide guidance for people to combine phage and antibiotics to treat .
抗生素耐药性正成为全球健康的最大威胁。与此同时，噬菌体疗法正再度受到关注。利用能感染并杀死细菌的噬菌体进行治疗是对抗抗生素耐药性的一种合适策略。此外，噬菌体越来越多地与标准抗生素联合使用以对抗耐药病原体。有趣的是，我们发现工程分枝杆菌噬菌体phAE159和天然噬菌体D29在卡那霉素、潮霉素或链霉素存在的情况下无法感染，但在壮观霉素存在的情况下噬菌体感染不受影响。基于对上述四种氨基糖苷类抗生素的一系列研究和结构分析，可以推测氨基糖苷类的氨基糖基团可能选择性抑制分枝杆菌噬菌体DNA复制。我们关于广谱抗生素抑制噬菌体感染的发现具有重要价值。这项研究将为人们联合使用噬菌体和抗生素治疗 提供指导。
